| Abstrakt: |
Of the 26 patients with NPM1 + FLT3+ AML, 12 patients (48%) expressed HLA-DR and seven patients (27%) expressed CD34. Three patients (8%) developed primary graft failure, nine patients (24%) developed acute graft versus host disease (GVHD), 13 (35%) developed chronic GVHD, CMV reactivation was detected in 28 patients (75%).Two patients developed metastatic squamous cell carcinoma, both died 5.5 and 12 years post-alloHSCT, both had cGVHD of the mouth and none has received irradiation. Thirteen patients (20.3%) had VTE events at diagnosis of which 10 patients had DVT, and three patients had PE. Further filtering of these patients and those from MDT provided a list of recruited patients ( I n i = 10, at time of writing); this comprises seven patients from the Royal London Hospital, two patients from St Bartholomew's Hospital and one patient from Hammersmith Hospital. BSH23-EP13 UK healthcare professional experiences with intensive chemotherapies for AML: Survey of toler... Dr Priyanka Mehta 1, Dr Joe Cross 1, Ms Hayley Kuter 2, Dr Mariette Odabashian 2, Mr Emil... 1 University Hospitals of Bristol and Weston NHS Trust, Bristol, UK, 2 Jazz Pharmaceuticals,... B Background: b Patients with AML treated with intensive chemotherapy (IC) may experience a high symptom burden/prolonged hospitalisation; however, relative IC toxicities are difficult to gauge from patient experience as patients typically receive only one regimen. [Extracted from the article] |
Plný text